Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated